ADA Scientific Sessions 2025 Abstract

Disparities in New Glucose-Lowering Drug Spending in U.S. Adults with Type 2 Diabetes (T2D), 2018–2022

By Ping Zhang, Yu Wang, Kai M. Bullard

Study in peoplePopulations

The paper

Ping Zhang, Yu Wang, Kai M. Bullard

Chamblee

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, oral 175-OR

doi.org/10.2337/db25-175-or

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk